| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8439307 | European Journal of Cancer | 2018 | 9 Pages |
Abstract
Nab-P/G administrations in our pts with cholestatic hyperbilirubinaemia suffering from APC were feasible and safe with respect to individualised dose administrations. A multicenter phase 1 trial in pts with hyperbilirubinaemia is started (AIO-PAK-0117) to confirm these findings in a prospective setting.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Uwe Pelzer, Lilianna Wislocka, Anja Jühling, Jana Striefler, Fritz Klein, Josefine Roemmler-Zehrer, Marianne Sinn, Tim Denecke, Marcus Bahra, Hanno Riess,